# Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLC

> **NCT00787267** · PHASE2 · TERMINATED · sponsor: **Duke University** · enrollment: 37 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Dasatinib

## Key facts

- **NCT ID:** NCT00787267
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-09
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 37 (ACTUAL)
- **Why stopped:** Poor accrual
- **Last updated:** 2016-06-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00787267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00787267, "Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00787267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*